Companies › Tesaro
3 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Niraparib Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | PARP2, PARP1 | Phase 3 | Ovarian Neoplasms | Apr 2029 |
| Cobolimab (TSR-022) Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 1 | Neoplasms | Mar 2027 |
| TSR-033 | – | Phase 1 | Neoplasms | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02655016 | Niraparib | Phase 3 | Ovarian Neoplasms | Oncology | May 2019 |
| NCT02817633 | Cobolimab (TSR-022) | Phase 1 | Neoplasms | Oncology | Mar 2027 |
| NCT02817633 | TSR-033 | Phase 1 | Neoplasms | Oncology | Mar 2027 |
| NCT03602859 | Niraparib | Phase 3 | Ovarian Neoplasms | Oncology | Apr 2029 |
AstraZeneca Merck & Co. (MSD) GSK Pfizer Johnson & Johnson (Janssen) BeiGene Impact Therapeutics pharmaand Allarity Therapeutics Boryung Pharmaceutical
pharmaand Immatics US Vividion Therapeutics Vyriad Takara Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.